HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

DGX

Quest Diagnostics Incorporated (S&P 500)

Healthcare — Diagnostics & Research

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Buy 2.2 / 5 16 analysts
$235.94
+$4.10 (+1.77%)
Target: $242.38 (2.7%)
Sign in to add DGX to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$26.04B
P/E Ratio (TTM)25.07
Forward P/E19.70
EPS (TTM)$9.41
Dividend Yield1.48%
Profit Margin9.19%
Revenue Growth10.20%
ROE14.60%
Debt/Equity81.07
Recommendation Buy 2.2
Analyst Target$242.38
Analysts16
Indexes S&P 500

Technical Indicators

RSI (14)78.7
Beta0.57
SMA 20$213.82
SMA 40$207.07
52-Week High$240.03
52-Week Low$166.75
50-Day Avg$203.25
200-Day Avg$193.00
Avg Volume928.2K
Volume$1.35M

Performance Analysis

NEUTRAL

DGX presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($240.03), which may indicate limited upside.
- RSI at 78.7 indicates overbought conditions — a pullback may be due.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 10.2% year-over-year.
+ Wall Street consensus is "Buy" from 16 analysts.
+ Average analyst target of $242.38 implies 2.7% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:00 UTC

Back to Screener Export Report